HDAC9 and cancer: Based on the above discussions, it is conceivable that the anti-CSC effect of pan-HDAC inhibitors is likely attributable to multiple signaling pathways in a cancer type- and/or inhibitor-specific manner, which might involve more than one HDAC isoform.